Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas

Pathology Research and Practice

Volumn 207, Issue 1, 2011, Pages 24-29

  Zhang, Yan ^a,b   Zhan, Hongfeng ^a   Xu, Wenlin ^a   Yuan, Zhicheng ^a   Lu, Peisong ^a   Zhan, Liping ^a   Li, Qiaoyu ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Glioma; Matrix metalloproteinases; Prognosis; Protease activated receptors

Indexed keywords

INTERSTITIAL COLLAGENASE; NITROSOUREA; PROTEINASE ACTIVATED RECEPTOR 1;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR BIOPSY; UPREGULATION;

BIOPSY; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PROGNOSIS; RECEPTOR, PAR-1; UP-REGULATION;

EID: 78650239814     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.10.003     Document Type: Article

References (33)

1. Noble M., Dietrich J. The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci. 2004, 27:148-154.
2. Kleihues P., Sobin L.H. World Health Organization classification of tumors. Cancer 2000, 88:2887.
3. Uematsu M., Ohsawa I., Aokage T., Nishimaki K., Matsumoto K., Takahashi H. Prognostic significance of the immunohistochemical index of surviving in glioma: a comparative study with the MIB-1 index. J. Neurooncol. 2005, 72:231-238.
4. Strojnik T., Kavalar R., Zajc I., Diamandis E.P., Oikonomopoulou K., Lah T.T. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res. 2009, 29:3269-3279.
5. Balzarotti M., Fontana F., Marras C., Boiardi A., Croci D., Ciusani E., Salmaggi A. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol. Res. 2006, 16:245-250.
6. Pei D. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell 2005, 7:207-208.
7. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloprotease family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 1996, 149:273-282.
8. Poola I., DeWitty R.L., Marshalleck J.J., Bhatnagar R., Abraham J., Leffall L.D. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat. Med. 2005, 11:481-483.
9. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 1998, 185:256-261.
10. Migita T., Sato E., Saito K. Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse and intestinal-type gastric carcinoma. Int. J. Cancer 1999, 84:74-79.
11. Stojic J., Hagemann C., Haas S., Herbold C., Kühnel S., Gerngras S., Roggendorf W., Roosen K., Vince G.H. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci. Res. 2008, 60:40-49.
12. Conant K., Hillaire C.S., Nagase H., Visse R., Gary D., Haughey N., Anderson C., Turchan J., Nath A. Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt. J. Biol. Chem. 2004, 279:8056-8062.
13. Boire A., Covic L., Agarwal A., Jacques S., Sharifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
14. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
15. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 2005, 3:1800-1814.
16. O'Brien P.J., Molino M., Kahn M., Brass L.F. Protease activated receptors: theme and variations. Oncogene 2001, 20:1570-1581.
17. Tantivejkul K., Loberg R.D., Mawocha S.C., Day L.L., John L.S., Pienta B.A. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J. Cell. Biochem. 2005, 96:641-652.
18. Yin Y.J., Salah Z., Grisaru-Granovsky S., Cohen I., Even-Ram S.C., Maoz M. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler. Thromb. Vasc. Biol. 2003, 23:940-944.
19. Yuan T.C., Lin M.F. Protease-activated receptor 1: a role in prostate cancer metastasis. Clin. Prostate Cancer 2004, 3:189-191.
20. Tellez C., Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003, 22:3130-3137.
21. Tellez C., McCarty M., Ruiz M., Bar-Eli M. Loss of activator protein-2a results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J. Biol. Chem. 2003, 278:46632-46642.
22. Yang E., Boire A., Agarwal A., Nguyen N., O'Callaghan K., Tu P., Kuliopulos A., Covic L. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 2009, 69:6223-6231.
23. Mansfield L., Subramanian A., Devalia H., Jiang W., Newbold R.F., Mokbel K. HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR. Anticancer Res. 2007, 27:2265-2268.
24. Shi X., Gangadharan B., Brass L.F., Ruf W., Mueller B.M. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol. Cancer Res. 2004, 2:395-402.
25. Ho I.A., Chan K.Y., Ng W.H., Guo C.M., Hui K.M., Cheang P., Lam P.Y. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 2009, 27:1366-1375.
26. Hatziapostolou M., Polytarchou C., Panutsopulos D., Covic L., Tsichlis P.N. Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res. 2008, 68:1851-1861.
27. Goerge T., Barg A. Schnaeker E-M tumor-derived matrix metalloprotease-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006, 66:7766-7774.
28. Agarwal A., Covic L., Sevigny L.M., Kaneider N.C., Lazarides K., Azabdaftari G., Sharifi S., Kuliopulos A. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther. 2008, 7:2746-2757.
29. Junge E.C., Lee J., Hubbard K.B., Zhang Z., Olson J.J., Hepler J.R., Brat D.J., Traynelis S.F. Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp. Neurol. 2004, 188:94-103.
30. Nguyen N., Kuliopulos A., Graham R.A., Covic L. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res. 2006, 66:2658-2663.
31. Sunami E., Tsuno N., Osada T., Saito S., Kitayama J., Tomozawa S., Tsuruo T., Shibata Y., Muto T., Nagawa H. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000, 5:108-114.
32. de Lourdes Suárez Roa M., Asbun J., Ruiz A., Ruiz Godoy L.M., Meneses García A. Expression of MMP-1 and MMP-11 in squamous cell carcinoma of the nasal cavity and paranasal sinuses. Patología 2008, 46:209-214.
33. Meneses-García A., Betancourt A.M., Abarca J.H., Montes A.B., Roa L.S., Ruíz-Godoy L. Expression of the metalloproteases MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, TIMP-1 and TIMP-2 in angiocentric midfacial lymphomas. World J. Surg. Oncol. 2008, 6:114.